2. Search Result
Search Result
Results for "

entry

" in MedChemExpress (MCE) Product Catalog:

204

Inhibitors & Agonists

3

Screening Libraries

4

Fluorescent Dye

4

Biochemical Assay Reagents

23

Peptides

12

Inhibitory Antibodies

24

Natural
Products

19

Recombinant Proteins

2

Isotope-Labeled Compounds

3

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7934
    Trachelogenin

    (-)-Trachelogenin

    		 HCV Infection Neurological Disease Inflammation/Immunology
    Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .
    Trachelogenin
  • HY-138102
    SSAA09E3

    		SARS-CoV Infection
    SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC50 of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM .
    SSAA09E3
  • HY-129116
    SSAA09E1

    		SARS-CoV Cathepsin Infection
    SSAA09E1 is a cathepsin L blocker (IC50: 5.33 μM).SSAA09E1 inhibits stages of viral entry. SSAA09E1 can be used for SARS-CoV infection research
    SSAA09E1
  • HY-133735A
    GRP-60367 hydrochloride
    1 Publications Verification

    		 RABV Infection
    GRP-60367 hydrochloride is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains. GRP-60367 hydrochloride specifically targets the RABV G protein .
    GRP-60367 hydrochloride
  • HY-174150
    EBOV entry-IN-2

    		Filovirus Infection
    EBOV entry-IN-2 (compound 16) is an EBOV entry inhibitor with an EC50 of 4.42 μM. EBOV entry-IN-2 shows metabolic stability .
    EBOV entry-IN-2
  • HY-173508
    EBOV entry-IN-1

    		Filovirus Infection
    EBOV entry-IN-1 (compound Hu7) is an EBOV entry inhibitor with an IC50 of 1.50 μM .
    EBOV entry-IN-1
  • HY-133735
    GRP-60367

    		RABV Infection
    GRP-60367 is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains .
    GRP-60367
  • HY-156441
    SARS-CoV-2-IN-65

    		SARS-CoV Infection
    SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .
    SARS-CoV-2-IN-65
  • HY-105086
    Pamaqueside

    CP148623

    		 SARS-CoV Infection Metabolic Disease
    Pamaqueside (CP148623) is a cholesterol absorption inhibitor and a potent binder of the SARS-CoV-2 receptor-binding domain (RBD), which may inhibit viral cellular entry. Pamaqueside can be utilized in metabolic and antiviral research .
    Pamaqueside
  • HY-163362
    HIV-1 inhibitor-65

    		Reverse Transcriptase PKC HIV Infection
    HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC50: 2.9 nM) and an activator of protein kinase C (PKC). HIV-1 inhibitor-65 inhibits syncytium formation (EC50: 7.0 nM) and inhibits HIV-1 entry and HIV-1 reverse transcriptase .
    HIV-1 inhibitor-65
  • HY-144110
    HCV-IN-37

    		HCV Infection
    HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .
    HCV-IN-37
  • HY-131059
    CBS1117

    		Influenza Virus Infection
    CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). CBS1117 interferes with the hemagglutinin (HA)-mediated fusion process .
    CBS1117
  • HY-157249
    Antiviral agent 43

    		Influenza Virus Infection
    Antiviral agent 43 (compound 16) is a potent and orally active influenza A viruses entry inhibitor. Antiviral agent 43 inhibits replications of influenza A strains VH04-H5N1 and PR8-H1N1 with EC50s of 240 nM and 72 nM, respectively .
    Antiviral agent 43
  • HY-N4100
    Trilobatin
    3 Publications Verification

    		 TNF Receptor HIV SGLT Infection
    Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd , Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects . Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
    Trilobatin
  • HY-N4100R
    Trilobatin (Standard)

    		TNF Receptor Reference Standards HIV SGLT Infection
    Trilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd , Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects . Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
    Trilobatin (Standard)
  • HY-164480
    GTCpFE

    		IKK NF-κB Inflammation/Immunology Cancer
    GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44 + CD24 - immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers .
    GTCpFE
  • HY-131069A
    MBX2329

    		Influenza Virus Infection
    MBX2329, a potent influenza virus inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC90 of 8.6 μM. MBX2329 inhibits a wide spectrum of influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic avian influenza (HPAI) virus A/H5N1, and oseltamivir-resistant A/H1N1 strains .
    MBX2329
  • HY-19663
    Lemildipine

    NB-818; NPK-1886

    		 Calcium Channel Cardiovascular Disease
    Lemildipine is a new dihydropyridine calcium entry blocker.
    Lemildipine
  • HY-P5404
    SAP6

    		SARS-CoV Others
    SAP6 is a biological active peptide. (inhibited virus entry into the cells)
    SAP6
  • HY-115488A
    BNM-III-170

    		HIV Infection
    BNM-III-170 is able to inhibit HIV-1 viral entry into target cells.
    BNM-III-170
  • HY-144106
    HCV-IN-33

    		HCV Infection
    HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor .
    HCV-IN-33
  • HY-118327
    Maleuric acid

    N-carbamylmaleamic acid

    		 DNA/RNA Synthesis Mitosis Cancer
    Maleuric acid has cytotoxicity on Ehrlich ascites tumor cells by preventing the entry of preprophase cells into mitosis.
    Maleuric acid
  • HY-A0079
    Tetracaine

    Amethocaine

    		 Sodium Channel Neurological Disease
    Tetracaine is a long-acting amino-ester used to prevent pain and induce anesthesia for the eyes; works by interfering with entry of sodium ions into nerve cells.
    Tetracaine
  • HY-P1034
    DAPTA
    2 Publications Verification

    D-Ala-peptide T-amide; Adaptavir

    		 CCR HIV Infection Endocrinology
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.
    DAPTA
  • HY-N3222
    Myriceric acid B

    		HIV Infection Cancer
    Myriceric acid B is a potent HIV-1 entry inhibitor targeting gp41. Myriceric acid B is an antitumor agent .
    Myriceric acid B
  • HY-111325
    Synta66
    4 Publications Verification

    		 CRAC Channel Neurological Disease
    Synta66 is an inhibitor of store-operated calcium entry channel Orai, which forms the pore of the CRAC channel, and used for the research of neurological disease.
    Synta66
  • HY-N1370
    Tanshinone IIA sulfonate sodium
    5+ Cited Publications

    Sodium Tanshinone IIA sulfonate; Tanshinone IIA sodium sulfonate

    		 CRAC Channel Cardiovascular Disease Cancer
    Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca 2+ entry (SOCE), and is used to treat cardiovascular disorders.
    Tanshinone IIA sulfonate sodium
  • HY-100039
    YYA-021

    		HIV Infection
    YYA-021 is a small-molecule CD4 mimic that inhibits HIV entry, with high anti-HIV activity and low cytotoxicity .
    YYA-021
  • HY-146157
    SARS-CoV-2-IN-22

    		SARS-CoV Infection
    SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM .
    SARS-CoV-2-IN-22
  • HY-N0248
    Saikosaponin B2

    		HCV Infection Cancer
    Saikosaponin B2 is an active component from Bupleurum chinensis root, acts as an entry inhibitor against HCV infection . Anti-cancer activity .
    Saikosaponin B2
  • HY-122331
    Norbormide

    		Calcium Channel Cardiovascular Disease
    Norbormide, a rodenticide, is a calcium entry blocker with a selective vasoconstrictor activity. Norbormide shows species- and tissue-specific, endothelium independent, and is restricted to the peripheral arteries of rat .
    Norbormide
  • HY-B0338
    Rimantadine

    1-Rimantadine

    		 Influenza Virus Autophagy Infection
    Rimantadine (1-Rimantadine) is an orally active inhibitor for M2 protein, which blocks the hydrogen ion channel activity, prevents the entry and replication of the virus, and exhibits board-spectrum antiviral activity. Rimantadine significantly inhibits hepatitis A virus (HAV) replication at the post-entry stage in Huh7 cells. Rimantadine enhances autophagy. Rimantadine has a significant protective effect against H3N2 virus in mouse model .
    Rimantadine
  • HY-170424
    D-myo-Inositol-1,3,4,5-tetrakisphosphate potassium

    		Biochemical Assay Reagents Others
    D-myo-Inositol-1,3,4,5-tetrakisphosphate potassium increases the extracellular Ca 2+ entry through upregulation of voltage-gated calcium channels .
    D-myo-Inositol-1,3,4,5-tetrakisphosphate potassium
  • HY-100229
    Aloxistatin
    Maximum Cited Publications
    71 Publications Verification

    E64d; E64c ethyl ester

    		 Cathepsin SARS-CoV Neurological Disease
    Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor. Aloxistatin (E64d) exhibits entry-blocking effect for MERS-CoV.
    Aloxistatin
  • HY-150756
    EBOV-GP-IN-1

    		Filovirus Infection
    EBOV-GP-IN-1 (Compound 28) is a potent Ebola entry inhibitor with an IC50 of 0.05 μM against Ebola virus envelope glycoprotein (EBOV-GP) .
    EBOV-GP-IN-1
  • HY-B0338A
    Rimantadine hydrochloride

    		Influenza Virus Autophagy Infection
    Rimantadine hydrochloride (Flumadine hydrochloride) is an orally active inhibitor for M2 protein, that blocks the hydrogen ion channel activity, prevents the entry and replication of the virus, and exhibits board-spectrum antiviral activity .
    Rimantadine hydrochloride
  • HY-158097
    IAV-IN-2

    		Influenza Virus Infection
    IAV-IN-2 (Compound MC-22) inhibits for Influenza A Virus (IAV) through blocking the entry of IAV into host cell via clathrin-mediated endocytosis (CME) .
    IAV-IN-2
  • HY-112913
    SOCE inhibitor 1

    		CRAC Channel Neurological Disease Metabolic Disease
    SOCE inhibitor 1 (Compound 39) is a store-operated calcium entry (SOCE) inhibitor with an IC50 of 4.4 μM. SOCE inhibitor 1 has a good stability in plasma .
    SOCE inhibitor 1
  • HY-P9803
    Anti-SARS-80R mAb

    SARS-80R; SARS Antibody-80R

    		 SARS-CoV Infection
    Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
    Anti-SARS-80R mAb
  • HY-W278021
    BTA-1

    		Amyloid-β Others
    BTA-1 is an uncharged derivative of thioflavin-T. BTA-1 has a high affinity for Aβ fibrils and shows very good brain penetration and clearance .
    BTA-1
  • HY-N0360
    Dihydrotanshinone I
    5+ Cited Publications

    		 SARS-CoV Cardiovascular Disease
    Dihydrotanshinone I is a natural compound extracted from Salvia miltiorrhiza Bunge which has been widely used for treating cardiovascular diseases. Dihydrotanshinone I exhibits entry-blocking effect for MERS-CoV.
    Dihydrotanshinone I
  • HY-158305
    SM51a

    		Others Others
    SM51a is a small molecule targeting ligand. SM51a can be linked to the 3' or 5' end of a sense strand or an antisense strand of a DUX4 RNAi agent for promoting it entry into cells .
    SM51a
  • HY-158306
    SM45a

    		Others Others
    SM45a is a small molecule targeting ligand. SM45a can be linked to the 3' or 5' end of a sense strand or an antisense strand of a DUX4 RNAi agent for promoting it entry into cells .
    SM45a
  • HY-150269
    RS5517

    		Na+/H+ Exchanger (NHE) Cancer
    RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer .
    RS5517
  • HY-119293A
    K777 tosylate

    		Cathepsin CCR Cytochrome P450 Parasite SARS-CoV Filovirus Infection Cancer
    K777 tosylate is a potent, orally active and irreversible cysteine protease inhibitor. K777 tosylate is also a potent CYP3A4 inhibitor with an IC50 of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 tosylate irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 tosylate is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 tosylate inhibits SARS-CoV and EBOV pseudovirus entry with IC50 values of 0.68 nM and 0.87 nM, respectively .
    K777 tosylate
  • HY-119293
    K777
    1 Publications Verification

    		 Cathepsin CCR Cytochrome P450 Parasite SARS-CoV Filovirus Infection Cancer
    K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent CYP3A4 inhibitor with an IC50 of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC50 values of 0.68 nM and 0.87 nM, respectively .
    K777
  • HY-P99028
    Ibalizumab

    TMB-355; TNX-355

    		 HIV Infection
    Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research .
    Ibalizumab
  • HY-161844
    Virapinib

    		SARS-CoV Infection
    Virapinib is a macropinocytosis inhibitor with antiviral activities. Virapinib inhibits macropinocytosis, limiting this entry route for the viruses. Virapinib inhibits infection by SARS-CoV-2, as well as by additional viruses, such as mpox virus and TBEV .
    Virapinib
  • HY-P99337
    Ansuvimab

    Ansuvimab-zyk; mAb114

    		 Filovirus Infection
    Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
    Ansuvimab
  • HY-N2037B
    (S)-Higenamine

    (S)-Norcoclaurine

    		 Endogenous Metabolite Others
    (S)-Higenamine ((S)-Norcoclaurine), a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS) .
    (S)-Higenamine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: